JAK2 and acquired polycythemia vera: Most patients with PV have activating mutations in JAK2, including JAK2V617F (95%–97%) and JAK2 exon 12 mutations (2%–4%; Pardanani, Lasho, Finke, Hanson, & Tefferi, 2007; Passamonti et al., 2010).